Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Research

Ankasa Regenerative Therapeutics

Sanford J. Madigan

Albert Your

Stefanie Monica Gaster, Ph.D.

Gloria Matthews

The leadership team at Ankasa Regenerative Therapeutics has a wealth of experience in the biotech industry. The team's experience spans research and development, clinical operations, and management. The team is also highly educated, with degrees from top universities in the United States.

Leadership Team

About

Team members